"The Global Autoimmune Disease Diagnostic
Market is expected to surpass US$ 18 Billion by the year end of 2025."
Through its Amplidiag and Novodiag solutions, Mobidiag offers a comprehensive range of fast, reliable and cost-effective molecular diagnostic
solutions for the detection of infectious diseases to laboratories of all sizes.
In April 2018, Blue Earth Diagnostics
expanded its prostate cancer portfolio through the acquisition of exclusive, worldwide rights to a broad family of Prostate Specific Membrane Antigen -targeted radiohybrid agents for cancer.
North America was the key region in global cancer diagnostics
market in terms of revenue in 2014, followed by Europe.
One of the main limitations of traditional companion diagnostics
is the narrow scope of biomarker evaluation and the often high tissue requirements if multiple single biomarker tests are needed for therapy selection.
In 2009 Swinton Technology partnered with DP Diagnostics
to create the industry ready "Prognosis" DP meter diagnostic
provides integrated, high-performance analytical systems to optimize laboratory management from pre-analytical to post-analytical processes.
An overview of current TB diagnostics
is given in the second chapter.
For companies that make products for nucleic acid preparation and analysis for research applications, the transition to molecular diagnostics
is a natural progression as their technology platforms can also be utilized to analyze patient samples for diagnostic
QIAGEN N.V., a Netherlands holding company, is a leading provider of innovative technologies and products for pre-analytical sample preparation and molecular diagnostics
Both firms are active in the immunochemistry business, a sub-segment of IVD, which involves diagnostics
for fertility, allergies, cancer and other pathologies.